Evan David Seigerman
Stock Analyst at BMO Capital
(3.39)
# 971
Out of 4,711 analysts
30
Total ratings
32.14%
Success rate
11.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Market Perform | $136 → $105 | $98.05 | +7.09% | 3 | Dec 20, 2024 | |
| REPL Replimune Group | Maintains: Outperform | $14 → $18 | $12.49 | +44.12% | 2 | Nov 22, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $228 → $208 | $175.58 | +18.46% | 5 | Nov 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $701.85 | +69.55% | 5 | Nov 1, 2024 | |
| NVO Novo Nordisk | Maintains: Outperform | $160 → $156 | $85.00 | +83.53% | 4 | Oct 17, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $27.90 | +258.42% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $263.38 | +34.79% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $26.36 | +36.57% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $8.75 | -65.71% | 1 | May 15, 2023 | |
| LLY Eli Lilly | Maintains: Outperform | $369 → $396 | $767.76 | -48.42% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 20, 2024
Downgrades: Market Perform
Price Target: $136 → $105
Current: $98.05
Upside: +7.09%
Replimune Group
Nov 22, 2024
Maintains: Outperform
Price Target: $14 → $18
Current: $12.49
Upside: +44.12%
AbbVie
Nov 12, 2024
Maintains: Outperform
Price Target: $228 → $208
Current: $175.58
Upside: +18.46%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $701.85
Upside: +69.55%
Novo Nordisk
Oct 17, 2024
Maintains: Outperform
Price Target: $160 → $156
Current: $85.00
Upside: +83.53%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $27.90
Upside: +258.42%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $263.38
Upside: +34.79%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.36
Upside: +36.57%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $8.75
Upside: -65.71%
Eli Lilly
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $767.76
Upside: -48.42%